CRESTONE – Clinical Study of REsponse to Seribantumab in Tumours with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 monoclonal antibody for Advanced or Metastatic Solid Tumours (MoST CRESTONE in Australia)

Posters & Oral Presentations

#10655 – Trials in Progress Virtual Poster Presentation

Presented at COSA 2021

Presenting Author: Dr Subotheni Thavaneswaran, Medical Oncologist at The Kinghorn Cancer Centre / Garvan Institute of Medical Research

Save this Presentation
Download PDF